1. Apply current guidelines and diagnostic testing performance in the diagnosis of Cushing’s disease.
2. Identify recurrent Cushing’s disease and use of potential treatment strategies.
3. Analyze current approved and off label pharmacologic therapies in the management of Cushing’s disease.
4. Review current safety, efficacy, and outcomes data in recent and ongoing clinical trials of emerging medical therapies for Cushing’s disease.
5. Evaluate patient cases during follow-up visits to optimize management of Cushing’s disease.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

FACULTY

James W. Findling, MD - Program Chair
Clinical Professor of Medicine and Surgery
Medical College of Wisconsin
Menomonee Falls, WI

Richard J. Auchus, MD, PhD
Professor of Internal Medicine
Professor of Pharmacology
James A Shayman and Andrea S Kevrick Professor of Translational Medicine
University of Michigan
Ann Arbor, MI

Susmeeta T. Sharma, MD
Director of Pituitary Endocrinology
MedStar Washington Hospital Center
Washington, DC

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

James W. Findling, MD: Consultant, Corcept Therapeutics, Recordati; Grant Recipient, Novartis Pharmaceuticals
Richard J. Auchus, MD, PhD: Consultant, Novartis Pharmaceuticals, Corcept Therapeutics, Jansen Pharmaceuticals, Quest Diagnostics, Strongbridge Biopharma, Crinetics Pharmaceuticals, Adrenas Therapeutics, PhaseBio Pharmaceuticals, OMass Therapeutics, Recordati Rare Diseases; Grant Recipient, Novartis Pharmaceuticals, Corcept Therapeutics, Neurocrine Biosciences, Spruce Biosciences
Susmeeta T. Sharma, MD: Research Investigator, Corcept Therapeutics

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Neena Natt, MD

The following SPC Committee members reported financial relationships:

• Andjela T. Drincic, MD: Advisory Board Member, Corcept
• Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
• Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
• Amy Rothberg, MD: Spouse, consultant of Merck
• Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Lorena Alarcon-Casas Wright, MD, Beret Casey, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by independent medical educational grants from Corcept Therapeutics Incorporated, HRA Pharma Rare Diseases and Recordati